Pfizer’s Wyeth Buy Rebuilds OTC Switch Potential
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's proposed $68 billion acquisition of Wyeth brings the return of a consumer health division and with it a pipeline structure for potential Rx-to-OTC switches
You may also be interested in...
Merck Reaffirms Commitment To Consumer Care In Restructuring
Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.
Novartis Seems Close to Consumer Health Sale – Analyst
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.
Novartis Seems Close to Consumer Health Sale – Analyst
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.